Cytek Biosciences (CTKB) Cash & Current Investments (2020 - 2026)

Cytek Biosciences (CTKB) has 7 years of Cash & Current Investments data on file, last reported at $65.7 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments fell 31.06% year-over-year to $65.7 million; the trailing twelve-month figure through Mar 2026 stood at $65.7 million (down 31.06% YoY), and the FY2025 full-year result was $90.9 million, down 7.99% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $65.7 million, down from $90.9 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $349.9 million in Q2 2022 and bottomed at $65.7 million in Q1 2026.
• The 5-year median for Cash & Current Investments is $162.3 million (2024), against an average of $174.1 million.
• The widest annual swing landed in 2022, when Cash & Current Investments soared 118.9%; it then sank 62.41% in 2023.
• A 5-year view of Cash & Current Investments shows it stood at $299.5 million in 2022, then tumbled by 44.03% to $167.6 million in 2023, then sank by 41.09% to $98.7 million in 2024, then retreated by 7.99% to $90.9 million in 2025, then retreated by 27.69% to $65.7 million in 2026.
• The last three Cash & Current Investments figures came in at $65.7 million (Q1 2026), $90.9 million (Q4 2025), and $93.3 million (Q3 2025), per Business Quant data.

Peer Comparison